This contract involves the ongoing supply of the medication Denosumab (M05BX04) as detailed in Appendix 1 of the Purchase Agreement - Price Offer. Suppliers are expected to deliver the specified pharmaceutical product in accordance with the tender conditions.
Contract awarded. Originally published 11 months ago.
This contract involves the ongoing supply of specific medications as outlined in Appendix 1 of the Purchase Agreement – Price Offer. The required medications include methotrexate (L04AX03), leflunomide (L04AA13), and hydroxychloroquine (P01BA02). Suppliers must adhere to the procurement conditions a
This contract involves the ongoing supply of medications as outlined in Appendix 1 of the Purchase Agreement – Price Offer. The supplies must include the pharmaceutical product Denosumab (M05BX04) in accordance with the tender conditions.
This contract involves the ongoing supply of the medication Certolizumab (L04AB05) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver the medication in accordance with the specified procurement conditions.
This contract involves the ongoing supply of the medication Etanercept (L04AB01) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver these pharmaceutical products in accordance with the specified procurement conditions.
Supply non-clinical consumables including forms, labels, and packaging for pathology and primary care services.
Procurement of RSV immunisation vaccine products for adult populations, scheduled for 2028.
Procurement for meningococcal ACWY vaccine supply in 2027 from qualified manufacturers or distributors.
Procurement opportunity for MMR vaccine supply with anticipated delivery timeline of 2027.
